Janelle Zeihen worried she’d have to file for bankruptcy after learning she owed $250,000 for her Crohn’s disease treatment.  The Milwaukee nursing home worker thought her insurance was covering the ...

AbbVie Inc. (NYSE:ABBV) reported an earnings per share (EPS) of $2.46, beating the estimated $2.38 and marking a 2.93% ...

AbbVie Inc (ABBV) surpasses expectations with robust sales growth in Skyrizi and Rinvoq, while navigating challenges in ...

As of Thursday’s close, the S&P 500 has a week-to-date gain of nearly 4%, the Dow Jones Industrial Average is up more than 2% ...

AbbVie Inc. beat revenue & EPS estimates, raised guidance due to Skyrizi & Rinvoq growth. Immunology shines; future ...

AbbVie has kicked off the year with a resounding success, exceeding expectations across multiple therapeutic areas. The ...

AbbVie stock inched higher Friday after the pharma titan hiked its outlook on the back of strength from its immunology ...

AbbVie took a little shot at the Trump administration’s trade policy, as the drugmaker said Friday that rather than tariffs, ...

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales ...

While management did not quantify any potential tariff exposure, it did signal that the effect would be in line with the ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics ...